Boston Scientific has announced the launch of the Promus Element Everolimus-Eluting Platinum Chromium Coronary Stent System in Japan. The product was recently approved by the Ministry of Health, Labor and Welfare.
The Promus Element stent system incorporates a platinum chromium (PtCr) alloy with an innovative stent design and an advanced catheter delivery system designed to provide physicians improved drug-eluting stent performance in treating patients with coronary artery disease. The company plans to begin marketing the product immediately in Japan.
“We are very pleased to launch the Promus Element stent system to Japanese physicians and their patients,” said Yusuke Naiki, president, Boston Scientific Japan. “This everolimus-based stent system complements our broad coronary intervention portfolio and reinforces our global leadership in the drug-eluting stent market.”
Boston Scientific received CE mark approval for the Promus Element stent system in 2009 and for the Promus Element Plus stent system in 2011. In the USA, the Promus Element Plus stent system was approved by FDA in 2011.
